Journal article icon

Journal article

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.

Abstract:

Few trials of glucose-lowering drugs or strategies in people with type 2 diabetes have investigated cardiovascular outcomes, even though most patients die from cardiovascular causes despite the beneficial effects of lipid-reducing and blood pressure-lowering treatments. The evidence-based reduction in risk of microvascular disease with glucose lowering has resulted in guidelines worldwide recommending optimisation of glycosylated haemoglobin, but no trial results have shown unequivocal cardio...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, OCDEM, Biomedical Research Centre
Califf, RM More by this author
Publisher:
Lancet Publishing Group
Journal:
Lancet
Volume:
383
Issue:
9933
Pages:
2008-2017
Publication date:
2014-06-05
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
URN:
uuid:a1c61524-aa1c-41d1-ac07-4c2ba4809a4e
Source identifiers:
469446
Local pid:
pubs:469446

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP